PIK3Ca mutation
Showing 1 - 25 of 3,520
Patterns Among PIK3CA Mutation in Advanced Breast Cancer
Completed
- Breast Cancer
-
East Hanover, New JerseyNovartis
Aug 1, 2023
PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)
Completed
- PIK3CA Mutation-Related Tumors
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Nov 9, 2023
A NIS of Alpelisib in Combination With Fulvestrant in
Not yet recruiting
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Alpelisib
- Fulvestrant
- (no location specified)
Aug 9, 2022
Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)
Recruiting
- Advanced Breast Cancer
-
Thalassery, Kerala, IndiaNovartis Investigative Site
Nov 21, 2022
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation Trial in San Francisco (Alpelisib, Carboplatin,
Not yet recruiting
- Solid Tumors, Adult
- +7 more
- Alpelisib
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jul 21, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer Trial (Evexomostat)
Not yet recruiting
- HR+/HER2-negative Breast Cancer
- Metastatic Breast Cancer
- (no location specified)
Jul 7, 2022
Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation Trial in United States (Serabelisib, Insulin Suppressing
Recruiting
- Advanced Solid Tumor
- +2 more
- Serabelisib
- Insulin Suppressing Diet
-
Birmingham, Alabama
- +9 more
May 25, 2022
Breast Cancer Trial in Shanghai (HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2))
Recruiting
- Breast Cancer
- HS-10352 combined with fulvestrant (Stage 1)
- HS-10352 combined with fulvestrant (Stage 2)
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 15, 2022
Patogenic Mutation in 5 Genes
Completed
- Colorectal Cancer
- +5 more
- co-occuring mutation
-
Jakarta, ALL, IndonesiaVania Myralda Giamour Marbun
Jul 21, 2021
Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer Trial in United States (TPST-1495 twice daily, TPST-1495 once daily
Recruiting
- Solid Tumor
- +8 more
- TPST-1495 twice daily
- +2 more
-
Baltimore, Maryland
- +8 more
Jan 4, 2023
Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation, Vascular Malformations Trial in Parkville (Alpelisib,
Not yet recruiting
- Slow-Flow Vascular Malformation
- +17 more
-
Parkville, Victoria, AustraliaThe Royal Children's Hospital
Aug 7, 2023
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +4 more
- Akt Inhibitor MK2206
- Laboratory Biomarker Analysis
-
Boston, Massachusetts
- +6 more
Jan 13, 2022
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Copanlisib
- +2 more
-
Los Angeles, California
- +4 more
Jul 19, 2022
Breast Cancer Trial in Italy (Ribociclib, Letrozole, Alpelisib)
Active, not recruiting
- Breast Cancer
- Ribociclib
- +3 more
-
Casale Monferrato, AL, Italy
- +40 more
Dec 3, 2021
HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)
Active, not recruiting
- HER2-positive Breast Cancer
- PIK3CA analysis
-
Rome, RM, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023
Metastatic Colorectal Cancer, PIK3CA Gene Mutation Trial (Alpelisib plus Capecitabine combination)
Not yet recruiting
- Metastatic Colorectal Cancer
- PIK3CA Gene Mutation
- Alpelisib plus Capecitabine combination
- (no location specified)
Feb 11, 2021
Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer Trial in Worldwide (AZD5363 when combined with
Completed
- Advanced or Metastatic Breast Cancer
- ER+ve Advanced or Metastatic Breast Cancer
- AZD5363 when combined with weekly paclitaxel.
- +2 more
-
Plovdiv, Bulgaria
- +40 more
Dec 23, 2022
Triple Negative Breast Tumors Trial in Worldwide (alpelisib, , nab-paclitaxel)
Active, not recruiting
- Triple Negative Breast Neoplasms
- alpelisib
- +2 more
-
Los Alamitos, California
- +154 more
Jan 12, 2023
HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer Trial in China (TQ-B3525, Fulvestrant injection)
Unknown status
- HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
- TQ-B3525
- Fulvestrant injection
-
Beijing, Beijing, China
- +3 more
Apr 20, 2020
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023